reference/18782211

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18782211

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
issn	1478-6354 1478-6362
issueIdentifier	2
pageRange	R95-
publicationName	Arthritis Research & Therapy
startingPage	R95
bibliographicCitation	Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012 Apr 27;14(2):R95. PMID: 22540992; PMCID: PMC3446469.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0ebff5da45fd851651eb2404dc55fc53 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_484d9ef9e1324fc09648021ce9dd6e15 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1725067db76682e8ce04ba49a501dfd4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a3094ca03de7655c4884a5239788cf49 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b10c9bfde33ff4eb2af976697408760 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0329955c4202bc46c9924808d3a78b4a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a85289247f7e54b0f210675ac75b83e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_21a6c99c2849e21021134e15f78e71fb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e27932fafb1f4c18405bf0c9c8968cb2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76b006b123efd7ee08aa6e47e01441a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-4780-8472 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7250-7239
date	2012-04-27^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1186/ar3819 https://pubmed.ncbi.nlm.nih.gov/22540992 https://pubmed.ncbi.nlm.nih.gov/PMC3446469
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/30289 https://portal.issn.org/resource/ISSN/1478-6354 https://portal.issn.org/resource/ISSN/1478-6362
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://scigraph.springernature.com/ https://www.crossref.org/
title	The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
discusses	http://id.nlm.nih.gov/mesh/M0011489 http://id.nlm.nih.gov/mesh/M0244307 http://id.nlm.nih.gov/mesh/M0544940
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D058846Q000627 http://id.nlm.nih.gov/mesh/D007370Q000235 http://id.nlm.nih.gov/mesh/D055106Q000379 http://id.nlm.nih.gov/mesh/D001172Q000188 http://id.nlm.nih.gov/mesh/D001172Q000235
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D053263Q000235 http://id.nlm.nih.gov/mesh/D011237 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000069283 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D053263Q000187 http://id.nlm.nih.gov/mesh/D005500 http://id.nlm.nih.gov/mesh/D017211 http://id.nlm.nih.gov/mesh/D008875
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6969 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_ab9bc7ce433266ca5b4543e538aeed73 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e7b77604e9c9ebff6ea7d7bc2d9c4c5e http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_17bb9037d3da80ba90ce710d0c2be4df http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_ecabfb8041fa675b8c84ffa0f3aaeb2e http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_88409759ef29f0a89d822df499d2698a http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8e93909207d656b026dfcac8be925198 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7d6a1edc08997e3d7b61d7a07051efb5 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9109 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_5e356f066ccf5676aa19b8ca5d03330e http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cdc2a110b1c83e44e60deee19e85dfdd http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_898a253558e8031d0e2ced9594ac3521 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8214

Showing number of triples: 1 to 65 of 65.